Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy

Completed · Phase 2 · Has a placebo group

Conditions studied: Dry Age-related Macular Degeneration, Geographic Atrophy

In brief

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug ACU-4429 in subjects with geographic atrophy.

Key facts

Study ID

NCT01002950

Run by

Kubota Vision Inc.

People needed

72

Starts

2009-10-01

Expected to finish

2012-10-01

Last updated by the study team

2014-03-11

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a clinical diagnosis of geographic atrophy, as defined in the protocol

You may not qualify if…

• Currently receiving or has received a medication prohibited by the protocol

Where it is running

• Retinal Consultants of Arizona — Phoenix, Arizona, United States
• Retina-Vitreous Associates Medical Group — Beverly Hills, California, United States
• Covance Clinical Research Unit, Inc. — Daytona Beach, Florida, United States
• National Ophthalmic Research Institute — Fort Meyers, Florida, United States
• Covance Clinical Research Unit, Inc. — Honolulu, Hawaii, United States
• Kresege Eye Institute — Detroit, Michigan, United States
• Associated Retinal Consultants, P.C. / William Beaumont Hospital — Royal Oak, Michigan, United States
• New York Eye and Ear Infirmary — New York, New York, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• Black Hills Regional Eye Institute — Rapid City, South Dakota, United States
• Covance Clinical Research Unit — Austin, Texas, United States
• Covance Clinical Research Unit, Inc. — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.